哌罗匹隆与利培酮治疗首发精神分裂症对照研究

Control study of perospirone and risperidone in treating firstepisode schizophrenia

目的探讨哌罗匹隆治疗首发精神分裂症的临床疗效及安全性。方法将124例首发精神分裂症患者按随机数字表法分为两组，每组62例。对照组予以利培酮治疗，观察组予以哌罗匹隆治疗，观察1个月。比较两组的临床疗效、简明精神病量表评分及不良反应发生率。结果观察组显效率为85．5％，对照组为69．4％，观察组显著高于对照组（P〈0．05）。治疗后两组简明精神病量表评分均较治疗前显著降低（P〈0．01），观察组显著低于对照组（P〈0．01）。观察组不良反应发生率为35．5％，对照组为58．1％，观察组显著低于对照组（P〈0．05）。结论哌罗匹隆治疗首发精神分裂症临床疗效显著，安全性高，优于利培酮。

Objective To investigate the clinic effect and safety of perospirone and risperidone in treating first-episode schizophrenia. Methods 124 cases with first-episode schizophrenia were selected and divided into two groups according to random number table, 62 cases in each group. Control group was given ris peridone treatment, observation group was given perospirone treatment, patients were observed for 1 month. Clinic effect, BPRS score, adverse reactions of the two groups were compared. Results Significant efficiency of observation group （85.5%） was significantly higher than control group （69.4G） （P〈 0.05）. BPRS score of the two groups after treatment were all declined （P〈0.01）, observation group was significantly lower than control group （P〈0.01）. Adverse reaction rate of observation group （35.5%）was significantly lower than control group （58.1%） （P〈0.05）. Conclusion Perospirone is better than risperidone in treating first-episode schizophrenia, it has significant clinic effect and higher safety.